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A B S T R A C T
Silybum marianum (milk thistle) is a medicinal plant used for the treatment of various liver disorders. This study
examined whether the main ﬂavonolignans from S. marianum (i.e. silybin, silychristin, silydianin) and their 2,3-
dehydro derivatives (i.e. 2,3-dehydrosilybin, 2,3-dehydrosilychristin, 2,3-dehydrosilydianin) activate the Nrf2
pathway, which regulates the expression of genes encoding many cytoprotective enzymes, including NAD(P)
H:quinone oxidoreductase 1 (NQO1). After 48 h of exposure, 2,3-dehydrosilydianin at concentrations of 25 μM
and higher signiﬁcantly elevated the activity of NQO1 in murine hepatoma Hepa1c1c7 cells. In contrast, other
tested compounds at non-cytotoxic concentrations had a mild or negligible eﬀect on the NQO1 activity. Using a
luciferase reporter assay, 2,3-dehydrosilydianin was found to signiﬁcantly activate transcription via the
antioxidant response element in stably transfected human AREc32 reporter cells. Moreover, 2,3-dehydrosily-
dianin caused the accumulation of Nrf2 and signiﬁcantly induced the expression of the Nqo1 gene at both the
mRNA and protein levels in Hepa1c1c7 cells. We found that 2,3-dehydrosilydianin also increased to some extent
the expression of other Nrf2 target genes, namely of the heme oxygenase-1 gene (Hmox1) and the glutamate-
cysteine ligase modiﬁer subunit gene (Gclm). We conclude that 2,3-dehydrosilydianin activates Nrf2 and induces
Nrf2-mediated gene expression in Hepa1c1c7 cells.
1. Introduction
Flavonolignans are plant polyphenols with a chemical structure
consisting of a ﬂavonoid and a lignan (phenylpropanoid) moiety. They
are found in some species of the families Asteraceae, Fabaceae,
Poaceae, and others [1]. The best known and most studied ﬂavono-
lignan is silybin [2], which together with silychristin and silydianin
(Fig. 1) are major components of silymarin, a standardized extract from
the fruits of Silybum marianum (milk thistle; Asteraceae). These
ﬂavonolignans originate biosynthetically from the ﬂavanonol taxifolin
(2,3-dihydroquercetin) and coniferyl alcohol. Their oxidation at the
ﬂavonoid moiety yields the corresponding 2,3-dehydroﬂavonolignans
(Fig. 1), formally derived from the ﬂavonol quercetin. Due to the low
stereoselectivity of the biosynthetic processes, silybin, silychristin and
also their 2,3-dehydro derivatives naturally occur as pairs of trans-
conﬁgured diastereomers/enantiomers, denoted A and B [3].
Silymarin is clinically used for its hepatoprotective eﬀects in the
complementary therapy of liver disorders caused by various hepato-
toxic compounds and viral infections. In addition, anticancer, cardio-
protective, neuroprotective, UV-protective, hypocholesterolemic and
some other eﬀects have been reported for silymarin in animal models
[4–7]. Although a wide range of molecular targets have been identiﬁed
in vitro for individual ﬂavonolignans, the protective potential of
silymarin is primarily attributed to its antioxidant action [4,7,8].
Phenolic compounds exert their antioxidant eﬀects through various
mechanisms including i) direct scavenging of reactive oxygen species
(ROS), ii) chelation of transition metal ions, iii) inhibition of ROS-
generating enzymes, and iv) upregulation of antioxidant enzymes [9].
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The direct antioxidant activity of silymarin ﬂavonolignans has been
investigated repeatedly [10–12]. In general, silychristin and silydianin
appear to be better radical scavengers than silybin [10,11], and
interestingly, 2,3-dehydroﬂavonolignans exhibit more potent free radi-
cal scavenging eﬀects than the corresponding compounds lacking the
2,3-double bond [11,12]. Silybin has also been characterized as an iron
chelator [13] and an inhibitor of prooxidant enzymes such as xanthine
oxidase and phagocyte NADPH oxidase [14]. Existing research suggests
that the beneﬁcial eﬀects of silymarin could also be associated with the
activation of the transcription factor NF-E2 p45-related factor 2 (Nrf2;
also called NFE2L2) [15]. Nrf2 controls the antioxidant response
element (ARE)-mediated expression of genes encoding various antiox-
idant and detoxication enzymes such as NAD(P)H:quinone oxidoreduc-
tase 1 (NQO1), heme oxygenase-1 (HMOX1), and glutamate-cysteine
ligase, composed of a catalytic (GCLC) and modiﬁer (GCLM) subunit
[16]. It has been reported that silymarin induces the expression of the
HMOX1 gene in human hepatoma Huh-7 cells [15], and modulates the
levels of Nrf2-regulated proteins in animals exposed to various toxic
agents [8]. Moreover, the daily oral administration of silybin to Sencar
mice for 3–15 days has been shown to elevate the activity of NQO1 in
various tissues [17], although the potential involvement of Nrf2 was
not investigated. In this study, we examined whether silybin, silychris-
tin, silydianin and their 2,3-dehydro derivatives activate the Nrf2
pathway in cells.
2. Materials and methods
2.1. Reagents for biological testing
Silybin (SB) was isolated from silymarin (Liaoning Senrong
Pharmaceutical, Panjin, China, batch No. 120501) as described pre-
viously [18]. Silychristin (SC) and silydianin (SD) were then isolated
from the silymarin devoid of SB as described in [18]. 2,3-Dehydrosi-
lybin (DHSB), 2,3-dehydrosilychristin (DHSC) and 2,3-dehydrosilydia-
nin (DHSD) were prepared by the oxidation of SB, SC and SD,
respectively. For the preparation of DHSB, see Ref. [19]; for the
preparation of DHSC and DHSD, see Ref. [11]. The purity of the tested
ﬂavonolignans was at least 95% (HPLC). Dimethyl sulfoxide (DMSO)
and sulforaphane were obtained from Sigma-Aldrich (St. Louis, MO,
USA).
2.2. Cell cultures and treatments
The murine hepatoma Hepa1c1c7 cell line (#95090613, ECACC,
Salisbury, UK) was cultured in Minimum essential medium α (M0894,
Sigma) supplemented with 2.2 g/L NaHCO3 and 10% heat- and
charcoal-treated fetal bovine serum (FBS). The stable human mammary
AREc32 reporter cell line [20] was cultured in Dulbecco's modiﬁed
Eagle's medium (#41966, Gibco, Grand Island, NY, USA) supplemented
with 2 mM glutamine and 10% FBS. Cells were maintained at 37 °C in a
humidiﬁed atmosphere containing 5% CO2. For experiments, cells were
seeded into multiwell plates and the experiments were performed after
24 h of stabilization in fresh complete culture medium. Cells were
treated with the tested compounds (in 0.1% (v/v) DMSO) and negative
controls were treated with 0.1% (v/v) DMSO alone.
2.3. Cell viability assay
Hepa1c1c7 cells (1 × 104 cells/well in 96-well plates) were treated
for 48 h with 0.1% (v/v) DMSO (control), 1.5% (v/v) Triton X-100
(positive control) or with the tested ﬂavonolignans. After treatment, the
cell viability was determined by MTT reduction assay. Cells were
washed with phosphate-buﬀered saline (PBS) and incubated for 2 h at
37 °C in serum-free medium containing 0.5 mg/mL 3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). After in-
cubation, the medium was removed and formazan produced by active
mitochondria was dissolved in DMSO containing 1% (v/v) ammonia.
The absorbance at 540 nm was measured on a spectrophotometric plate
reader and used to calculate relative cell viability, where cells treated
with DMSO alone represented 100% viability.
2.4. NQO1 activity assay
After the treatment of Hepa1c1c7 cells (1 × 104 cells/well in 96-
well plates), the activity of NQO1 was determined spectrophotometri-
cally as described previously [21]. Cells were washed four times with
PBS and lysed with 75 μL of digitonin solution (0.8 g/L digitonin, 2 mM
EDTA, pH 7.8) by shaking on an orbital shaker for 20 min at room
temperature. One part of the cell lysate (20 μL) was used to determine
the protein content. The remaining lysate (55 μL) was mixed with
200 μL of 0.5 M Tris-Cl buﬀer containing 10% (w/v) bovine serum
albumin, 1.5% (v/v) Tween-20, 7.5 mM FAD, 150 mM glucose-6-
Fig. 1. Chemical structures of tested ﬂavonolignans.
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phosphate, 2 U/mL glucose-6-phosphate dehydrogenase (Roche Diag-
nostics, Mannheim, Germany), 50 mM NADP+, 25 mM menadione and
0.7 mM MTT. The mixture was incubated for 5 min at room tempera-
ture and the reaction was stopped with 50 μL of dicumarol suspension
(0.3 mM dicumarol, 5 mM potassium phosphate, 0.5% DMSO). The
absorbance of the reduced MTT corresponding to the activity of NQO1
was measured at 610 nm on a spectrophotometric plate reader. The
absorbance values were normalized to the protein content and used for
the calculation of fold changes versus the control.
2.5. Gene reporter assay
AREc32 cells (1 × 104 cells/well in 96-well plates) were treated for
24 h with the tested compounds. After treatment, the plate was frozen
and kept at −20 °C for 24 h and then the luciferase activity was
measured on a GloMax-Multi+ microplate luminometer (Promega,
Madison, WI, USA) using the Bright-Glo Luciferase Assay System
(Promega). The luminescence values were normalized to the protein
content of the cells and used for the calculation of fold changes versus
the control.
2.6. Reverse transcription and quantitative real-time PCR
After the treatment of Hepa1c1c7 cells (4 × 105 cells/well in 6-well
plates), total RNA was extracted using TRI Reagent Solution (Applied
Biosystems, Foster City, CA, USA). RNA samples (2 μg) were reverse-
transcribed using a High-Capacity cDNA Reverse Transcription Kit
(Applied Biosystems) and real-time PCR was performed in a
LightCycler 480 II system (Roche) using TaqMan Universal PCR
Master Mix and TaqMan Gene Expression Assays, consisting of speciﬁc
primers and FAM dye-labeled TaqMan minor groove binder probes
(Applied Biosystems). The assay ID was Mm00477784_m1 for Nfe2l2
(Nrf2), Mm01253561_m1 for Nqo1, Mm00516005_m1 for Hmox1,
Mm00802655_m1 for Gclc, Mm00514996_m1 for Gclm and
Mm99999915_g1 for Gapdh. Ampliﬁcation conditions were 50 °C for
2 min, 95 °C for 10 min, followed by 40 cycles at 95 °C for 15 s and
60 °C for 1 min. Crossing point values, equivalent to CT, were deter-
mined using second derivative maximum analysis. Relative changes in
gene expression were calculated by the comparative CT method using
the 2−ΔΔCT equation with results normalized to Gapdh mRNA levels.
2.7. Western blot analysis
After the treatment of Hepa1c1c7 cells (4 × 105 cells/well in 6-well
plates), total cellular extracts were prepared as described previously
[22]. Aliquots containing an equal amount of protein were subjected to
sodium dodecyl sulfate-polyacrylamide gel electrophoresis using
4–12% NuPAGE Bis-Tris mini gels (Thermo Fisher Scientiﬁc, Waltham,
MA, USA), proteins were transferred to polyvinylidene diﬂuoride
membrane by electroblotting, and the membranes were probed with
appropriate primary antibodies. Rabbit monoclonal Nrf2 (D1Z9C) XP
(#12721) antibody was obtained from Cell Signaling Technology
(Danvers, MA, USA). Rabbit polyclonal heme oxygenase-1 (sc-10789)
and goat polyclonal actin (sc-1616) antibodies were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies against
NQO1, GCLC and GCLM were kindly provided by Professor John D.
Hayes (University of Dundee, Dundee, UK). Primary antibodies were
visualized with rabbit anti-goat or goat anti-rabbit horseradish perox-
idase-conjugated secondary antibodies using a chemiluminescent reac-
tion. The relative band intensities were determined by densitometric
analysis using ImageJ software (National Institutes of Health, Bethesda,
MD, USA).
2.8. Statistical analysis
Results were expressed as means ± standard deviation. The diﬀer-
ences in mean values were analyzed by one-way ANOVA with Tukey
post hoc test. A p value of< 0.05 was considered to be statistically
signiﬁcant.
3. Results and discussion
3.1. Eﬀect of tested ﬂavonolignans on NQO1 activity in Hepa1c1c7 cells
This study was designed to investigate the ability of six ﬂavono-
lignans to activate the Nrf2 pathway in cells. The study included i)
silybin, silychristin and silydianin, isolated from commercially avail-
able extract from the fruits of S. marianum [18,23], and ii) 2,3-
dehydrosilybin, 2,3-dehydrosilychristin and 2,3-dehydrosilydianin,
which were prepared by oxidation, by molecular oxygen under basic
conditions, of the compounds listed in the ﬁrst item [11,23]. Flavono-
lignans could be tested at concentrations of up to 50 μM with respect to
their solubility in the cell culture medium, nonetheless the maximum
ﬁnal concentrations of silybin, 2,3-dehydrosilybin and 2,3-dehydrosi-
lychristin were 12.5, 5 and 25 μM, respectively, to avoid cytotoxic
eﬀects. To identify whether any of the tested compounds stimulate Nrf2
activity, we evaluated their eﬀect on the activity level of NQO1 in
murine hepatoma Hepa1c1c7 cells, a well-established model for the
NQO1 assay [21]. NQO1 is a highly-inducible enzyme responsible,
among others, for a single-step two-electron reduction of quinones and
quinone imines, thus preventing the formation of reactive and toxic
semiquinone intermediates [24]. After the exposure of Hepa1c1c7 cells
for 48 h to 2.5 μM sulforaphane, a classical Nrf2 activator [25], the
activity of NQO1 increased 3.6-fold compared to the control (Fig. 2).
Among the tested ﬂavonolignans, only 2,3-dehydrosilydianin was
found to produce a signiﬁcant dose-dependent elevation in NQO1
activity. After 48 h, 25 and 50 μM 2,3-dehydrosilydianin increased
the activity of NQO1 to 1.4-fold and 1.9-fold, respectively, compared to
the control (Fig. 2). Other tested compounds had mild or negligible
eﬀects on the NQO1 activity, even at the highest concentrations tested.
After 48 h of incubation, the activity of NQO1 was 1.2-fold with
12.5 μM silybin, 1.1-fold with 5 μM 2,3-dehydrosilybin, 1.2-fold with
Fig. 2. Eﬀect of tested ﬂavonolignans on NQO1 activity in Hepa1c1c7 cells. Cells were treated for 48 h with 0.1% DMSO (control), 2.5 μM sulforaphane (SFN; positive control) or with
indicated concentrations of silybin (SB), 2,3-dehydrosilybin (DHSB), silychristin (SC), 2,3-dehydrosilychristin (DHSC), silydianin (SD) or 2,3-dehydrosilydianin (DHSD). After treatment,
the activity of NQO1 was determined using the NQO1 assay. Data are means ± standard deviation of three experiments. *p < 0.05; **p < 0.01, signiﬁcantly increased versus control.
L. Roubalová et al. Fitoterapia 119 (2017) 115–120
117
50 μM silychristin, 1.3-fold with 25 μM 2,3-dehydrosilychristin, and
0.9-fold with 50 μM silydianin (Fig. 2). Table 1 shows the eﬀect of
ﬂavonolignans on the viability of Hepa1c1c7 cells at the maximum
concentrations used and after 48 h of exposure. The above results
suggest that 2,3-dehydrosilydianin acts as an NQO1 inducer, and thus
may potentially activate Nrf2 at non-cytotoxic concentrations.
3.2. Activation of Nrf2 by 2,3-dehydrosilydianin in AREc32 reporter cells
The eﬀect of 2,3-dehydrosilydianin on the transcriptional activity of
Nrf2 was examined using stably transfected human AREc32 reporter
cells, which contain a luciferase reporter gene controlled by eight
copies of the ARE [20]. After the treatment of AREc32 cells for 24 h
with 2.5 μM sulforaphane, a positive control, the activity of luciferase
was increased 3.6-fold compared to the control (Fig. 3). We found that
2,3-dehydrosilydianin also induced a small but signiﬁcant elevation in
the luciferase activity. AREc32 cells treated for 24 h with 25 and 50 μM
2,3-dehydrosilydianin exhibited a 1.3-fold and 1.6-fold increase in the
luciferase activity, respectively, compared to the control (Fig. 3). These
results conﬁrm that 2,3-dehydrosilydianin can activate Nrf2-dependent
transcription in cells.
3.3. Accumulation of Nrf2 by 2,3-dehydrosilydianin in Hepa1c1c7 cells
The activity of Nrf2 depends on the interaction between Nrf2 and its
negative regulator, Kelch-like ECH-associated protein 1 (Keap1). Under
homeostatic conditions, Keap1 binds to Nrf2 and targets it for
ubiquitination and proteasomal degradation. In contrast, stress condi-
tions associated with the oxidation or covalent modiﬁcation of cysteine
residues in Keap1 and/or with the phosphorylation of Nrf2 inactivate
Keap1 and thus stabilize Nrf2, which in turn accumulates in the cell and
increases the expression of Nrf2 target genes [26]. Using quantitative
real-time PCR and Western blot analysis, we found that 50 μM 2,3-
dehydrosilydianin as well as 5 μM sulforaphane, a positive control [27],
elevated the protein levels of Nrf2 in Hepa1c1c7 cells after 3 and 24 h
of exposure (Fig. 4), while the levels of Nrf2 mRNA remained
unaﬀected, as shown after 6 h (Table 2). Although the eﬀect of 2,3-
dehydrosilydianin on the level of Nrf2 was much weaker than that of
sulforaphane (Fig. 4), the accumulation of Nrf2 corroborates the ability
of 2,3-dehydrosilydianin to increase the activity of Nrf2.
3.4. Eﬀect of 2,3-dehydrosilydianin on the expression of Nrf2 target genes
in Hepa1c1c7 cells
To further investigate the eﬀect of 2,3-dehydrosilydianin on
Hepa1c1c7 cells, we analyzed the expression of selected Nrf2 target
genes, including Nqo1, Hmox1, Gclc and Gclm. As expected, 5 μM
sulforaphane (a positive control) [27] signiﬁcantly increased the
expression of all four genes after 6 h of exposure (Table 2), and also
upregulated the protein levels of NQO1, HMOX1, GCLC and GCLM after
24 h (Fig. 4). In Hepa1c1c7 cells treated for 6 h with 2,3-dehydrosily-
dianin, we found a signiﬁcant increase in the expression of the Nqo1
gene. At concentrations of 25 and 50 μM, 2,3-dehydrosilydianin
elevated Nqo1 mRNA levels to 1.6-fold and 2.3-fold, respectively,
compared to the control. The expression of the other tested genes was
also aﬀected to some extent by 2,3-dehydrosilydianin, but only at a
concentration of 50 μM, where the increase in mRNA levels of Hmox1,
Gclc and Gclm were 2.2-fold, 1.3-fold and 1.5-fold, respectively
(Table 2). Western blot analysis showed that the changes in gene
expression induced in Hepa1c1c7 cells by 50 μM 2,3-dehydrosilydianin
were accompanied by an obvious increase in the protein levels of NQO1
and GCLM, while the levels of HMOX1 and GCLC remained almost
unchanged after 24 h of exposure (Fig. 4). These results show that 2,3-
dehydrosilydianin activates Nrf2-dependent gene expression. However,
this eﬀect is clearly evident only in the induction of a highly inducible
Nqo1 gene [28], and thus 2,3-dehydrosilydianin is a considerably
weaker Nrf2 activator than sulforaphane, which served as a positive
control in the study. Although our results cannot explain the lower
potency of 2,3-dehydrosilydianin compared to sulforaphane, we may
presume that the two compounds diﬀer in the mechanism by which
they activate Nrf2. The Nrf2 activation by sulforaphane, a natural
isothiocyanate, results from the covalent modiﬁcation of cysteine
residues of Keap1 by direct reaction with the electrophilic isothiocya-
nate group [26]. On the other hand, the eﬀect of 2,3-dehydrosilydianin
could be mediated through a more complex mechanism dependent on
the phosphorylation of Nrf2 by some protein kinase. This kind of
mechanism is involved in the Nrf2 activation by structurally related
compounds such as quercetin [29] and quercetin-7-gallate [27].
4. Conclusions
Our study examined the eﬀect of six ﬂavonolignans, namely of
silybin, silychristin, silydianin and of their 2,3-dehydro derivatives, on
the Nrf2 pathway. We have demonstrated that 2,3-dehydrosilydianin,
in contrast to the other tested compounds, activates the Nrf2-dependent
gene expression in vitro. This is mainly documented by the activation of
the antioxidant response element in AREc32 reporter cells, and by the
accumulation of Nrf2 and induction of NQO1 at the mRNA, protein and
activity levels in Hepa1c1c7 cells. The diﬀerence in the eﬀect of 2,3-
dehydrosilydianin and silydianin conﬁrms the importance of the 2,3-
double bond in the structure of ﬂavonolignans for certain biological
activities. For instance, 2,3-dehydrosilydianin was shown to inhibit tert-
butyl hydroperoxide-induced lipid peroxidation with a higher potency
than silydianin [11]. Similarly, 2,3-dehydrosilybin is a more potent
inhibitor of DNA topoisomerase I [30], cytochrome P450 1A1 [31] and
the glucose transporter GLUT4 [32] than silybin.
Since the main silymarin components silybin, silychristin and
Table 1
Eﬀect of tested ﬂavonolignans on the viability of Hepa1c1c7 cells.
Compound Concentration Viability (% of control)
DMSO 0.1% 100
SB 12.5 μM 107.9 ± 9.9
DHSB 5 μM 104.5 ± 10.9
SC 50 μM 122.4 ± 7.7
DHSC 25 μM 96.5 ± 9.0
SD 50 μM 118.3 ± 9.5
DHSD 50 μM 101.5 ± 15.7
Triton X-100 1.5% 0
Hepa1c1c7 cells were treated for 48 h with 0.1% DMSO (control), 1.5% Triton X-100
(positive control) or with indicated concentrations of silybin (SB), 2,3-dehydrosilybin
(DHSB), silychristin (SC), 2,3-dehydrosilychristin (DHSC), silydianin (SD) or 2,3-dehy-
drosilydianin (DHSD). Cell viability was determined by MTT assay. Data are means±
standard deviation of three independent experiments. The table shows the results for the
highest ﬂavonolignan concentrations tested in the NQO1 assay.
Fig. 3. Eﬀect of 2,3-dehydrosilydianin (DHSD) on ARE-driven gene expression in AREc32
reporter cells. Cells were treated for 24 h with 0.1% DMSO (control), 2.5 μM sulforaphane
(SFN; positive control) or with 12.5–50 μM DHSD. After treatment, luciferase reporter
activity was determined luminometrically and normalized to protein content. Data are
means ± standard deviation of three experiments. *p < 0.05; **p < 0.01, signiﬁcantly
increased versus control.
L. Roubalová et al. Fitoterapia 119 (2017) 115–120
118
silydianin did not activate the Nrf2 pathway, our results cannot explain
the eﬀects of silymarin and silybin on the expression and/or activity of
Nrf2-regulated proteins observed in vivo [8,17]. We can, however,
speculate that some eﬀects of silymarin may be mediated by minor
silymarin ﬂavonolignans (e.g. isosilybin) or by non-ﬂavonolignan
components [3,4], of which the ﬂavonoids taxifolin and quercetin were
recognized as Nrf2 activators [27,33,34]. Moreover, the formation of
potentially active metabolites should also be taken into account when
interpreting the in vivo bioactivity of silymarin and ﬂavonolignans.
Accordingly, we suggest that further research on 2,3-dehydrosilydianin
should be aimed at evaluating its eﬀect on the Nrf2 pathway in vivo and
identifying its metabolites.
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